676 Chris Moxham: Co-Founder & CEO of Transcripta Bio

Apr 16, 2025

Ask episode

Chapters

Transcript

Episode notes

On this episode of The Kara Goldin Show, we’re joined by Chris Moxham, CEO of Transcripta Bio, a biotech company revolutionizing drug discovery through the power of AI and transcriptomics. With a unique platform built on a vast perturbation atlas of small molecules, Transcripta is uncovering novel opportunities across a wide range of human diseases—faster and with more precision than traditional methods.
In our conversation, Chris shares the story behind Transcripta Bio and how the team is building frontier AI models to predict biological responses from potential drug compounds. We dive into what makes their approach different, why a transcriptome-first strategy matters, and how they're unlocking insights that have the potential to lead to more targeted and effective therapies. Chris also speaks about the mindset required to lead in a rapidly evolving industry, the collaboration between AI and human expertise, and what’s next for the company.
If you’re curious about the intersection of science and technology, the future of drug discovery, or the kind of leadership it takes to build something truly transformative, this episode is one you won’t want to miss. Now on The Kara Goldin Show.

Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks.

To learn more about Chris Moxham and Transcripta Bio:
https://www.transcriptabio.com
https://www.linkedin.com/in/christophermoxham
https://www.instagram.com/transcriptabio
https://www.linkedin.com/company/transcriptabio